J&J: FDA approval for Edurant Ped in HIV
This approval builds on Johnson & Johnson's long-standing commitment to ensuring that people living with HIV, including children, have treatment options that can work for them.
' Although the population of young children living with HIV is small, additional treatment options remain essential to ensure that every person living with HIV can benefit from a treatment regimen that works for them,' commented Penny Heaton, M.D., Global Therapeutic Area Manager, Infectious Diseases. and Vaccines at Johnson & Johnson.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction